Weekly company factor report
AUROPHARMA Valuation, Quality and Momentum
Aurobindo Pharma Limited
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Low valuation with strong finances
The company ranks at the 70th percentile for value and the 82th percentile for financial strength in this market.
Value supported by price performance
The value rank is 70/100 and the price-performance rank is 91/100. Both measures are above most companies in the selected market.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for AUROPHARMA.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Value measures compared
Raw multiples and yields
P/E history
P/E is shown only when trailing earnings are positive.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
The 12-month return excluding the latest month is 51%. Risk-adjusted price performance is 2.38, showing a high return relative to measured volatility. Near-term vol (46%) is expanding vs long-term (21%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.950 | Unchanged for 17 snapshots | stable |
| Value %ile | 0.700 | Unchanged for 1 snapshots | deteriorating |
| Quality %ile | 0.820 | Unchanged for 17 snapshots | deteriorating |
| Momentum %ile | 0.910 | Unchanged for 17 snapshots | improving |
| F-Score | 6.000 | Unchanged for 0 snapshots | stable |
| Confidence | 0.837 | Unchanged for 17 snapshots | deteriorating |
| Volatility | 0.214 | Unchanged for 0 snapshots | deteriorating |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| SPARC Sun Pharma Advanced Research Company Limited | 98.0 | 81.0 | 98.0 | 91.0 |
| LUPIN Lupin Limited | 96.0 | 76.0 | 99.0 | 75.0 |
| VENUSREM Venus Remedies Limited | 96.0 | 69.0 | 90.0 | 99.0 |
| LINCOLN Lincoln Pharmaceuticals Limited | 95.0 | 86.0 | 71.0 | 75.0 |
| STAR Strides Pharma Science Limited | 94.0 | 68.0 | 89.0 | 86.0 |
| SAGILITY Sagility Limited | 93.0 | 71.0 | 88.0 | 72.0 |
| ANUHPHR Anuh Pharma Limited | 89.0 | 76.0 | 63.0 | 72.0 |
| NATCOPHARM NATCO Pharma Limited | 89.0 | 76.0 | 64.0 | 70.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Quarterly figures
Revenue
Net income
Net margin
Operating income
Equity and liabilities
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 25 Sep 2026
Value supported by company results and completed price evidence
The main checks pass. The supporting research is ready for a full review.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- ✓ Company recordPassed · 85/100 Checks profitability, cash support, balance-sheet measures and their direction.
- ✓ Relative valuePassed · 70/100 Checks whether the current valuation compares well with the selected market.
- ✓ Market supportPassed · 96/100 Checks completed price performance, relative strength, trend and buying pressure.
- ✓ Setup and riskPassed · 76/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewReview now Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 82/100
- F-Score 6/9
- 4 usable annual periods
- Value rank 70/100
- P/E 28.1×
- Free-cash-flow yield +2.4%
- Price-performance rank 91/100
- Six-month return +30.3%
- Relative strength +0.6
- Stage 2 · Advancing
- Stage 2 · Advancing
- Price at -1.3% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 21.4%
- Recent volatility 45.7%
- 12-month drawdown -7.7%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
- Company record scores 85/100.
- Relative value scores 70/100.
- Market support scores 96/100.
- Setup scores 76/100.
What still needs attention
- No main check is currently below its working threshold.
Next check
Review the company figures, sector context, price chart and risk evidence together.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for AUROPHARMA are shown.